Patrys Limited · ASX:PAB
Patrys — Investor Presentation (July 2019)
27 slides from Patrys's investor presentation, Jul 24, 2019
Slide 1: ASX & Media Release: Updated investor presentation and attendance at Bioshares
ASX & Media Release Updated investor presentation and attendance at Bioshares For personal use only Melbourne, Australia; 24 July 2019: Patrys Limited (ASX: PAB, “Patrys” or the “Company”) is pleased to release an updated investor presentation. The presentation will be used to update to shareholders
Slide 2: ASX & Media Release (continued)
has been shown to significantly enhance the efficacy of both chemotherapy and radiotherapy. Further, Deoxymab 3E10 can be conjugated to nanoparticles to target delivery of chemotherapeutics and imaging agents to tumours. For personal use only Patrys has developed a humanised form of Deoxymab 3E10, P
Slide 3: Investor Presentation July 2019
For personal use only Investor Presentation July 2019 Dr James Campbell CEO and Managing Director Private & Confidential
Slide 4: Patrys has a world first cell-penetrating antibody platform
Patrys has a world first cell-penetrating antibody platform For personal use only Novel biologics Promising pre- Multiple options for Favourable platform clinical results development macro themes Antibody platform which Supresses tumour growth Multiple pre-clinical studies Large pre-clinical biologi
Slide 5: Biologics typically transact at an earlier stage and at higher valuations
Relative to small molecules, biologics typically transact at an earlier stage and at higher valuations For personal use only Proportion of total deals1 Number of pre-clinical deals1 Pre-clinical avg. deal size1,2 Majority of biologic deals occur at Significantly more interest in Pre-clinical biologi
Slide 6: Significant upside value underpinned by recent pre-clinical antibody deals
Significant upside value for Patrys underpinned by recent significant pre- clinical deals executed for antibody assets For personal use only Recent pre-clinical antibody transactions (licensing, asset and corporate)1 US$1,660m US$1,388m2 US$663m US$685m US$547m US$554m US$604m Deal date 4Q18 3Q18 3Q
Slide 7: PAT-DX1 supported by significant R&D investment and well positioned for the clinic
PAT-DX1 is supported by significant R&D investment and Patrys is well positioned to progress towards the clinic For personal use only Development timeline1 Complete two combination Deoxymab cancer therapy pre- applications clinical studies in discovered at TNBC & GBM Yale University First patent PAT
Slide 8: Proven Board and scientific advisory team
Proven Board and scientific advisory team with significant industry, clinical development and commercialisation experience For personal use only John Read Dr James Campbell Dr Allen Ebens Chairman Chief Executive Officer Scientific Advisory Board Chairman of multiple Multiple successful Established
Slide 9: A first-in-class antibody platform with potential to revolutionise cancer treatment
A first-in-class antibody platform with potential to revolutionise treatment across a broad range of cancers For personal use only Deoxymab 3E10 platform overview Differentiating features § Deoxymab 3E10 is the world’s first cell-penetrating anti-DNA antibody for the treatment of cancer ü Deoxymab 3
Slide 10: PAT-DX1 has a novel mechanism of action interfering with DNA repair
PAT-DX1 has a novel mechanism of action that interferes with tumour cell DNA repair processes For personal use only A novel mechanism of action… PAT-DX1 preferentially localises to tumours Tumour cells release “clouds” of § Specifically attracted to extracellular DNA from dying extracellular DNA can
Slide 11: Attaching nanoparticles to PAT-DX1 creates a cancer-targeting delivery vehicle
Attaching nanoparticles to PAT-DX1 creates a cancer-targeting delivery vehicle for a range of ‘cargoes’ (e.g. chemotherapeutics) For personal use only § Chemotherapeutics § Other antibodies § Small molecules PAT-DX1 NP PAT-DX1-NP § Other PAT-DX1 seeks out Patrys is testing the This characteristic Pa
Slide 12: Platform technology with broad applicability across multiple indications
Platform technology with broad applicability across multiple indications, with Patrys’ focus informed by disease mechanism and market attractiveness For personal use only Potential cancers Patrys could target and Patrys’ approach to prioritising and Incidence rates (US cases p.a.)1 selecting target
Slide 13: Prioritising two target indications to progress towards the clinic
Prioritising two target indications to progress towards the clinic For personal use only Metastatic triple-negative breast cancer Glioblastoma (MTNBC) (GBM) § In the US, Breast cancer is the second leading § GBM is a particularly aggressive, highly malignant cause of cancer death in women1 form of b
Slide 14: Key development pathways progressing well with positive pre-clinical data
Patrys’ key development pathways progressing well, with positive data from multiple pre-clinical studies generating industry interest For personal use only Single agent and Combination Conjugation approach PAT-DX1 PAT-DX1-NP Validated by years of 25+ 11+ 8+ 6 scientific Pre-clinical Animal Years of
Slide 15: Development program fully funded to date
Patrys’ development program is fully funded to date and expected to release additional pre-clinical data in the near term For personal use only Discovery Pre-clinical Status PAT-DX1 + radiation Single agent (TNBC brain mets) ü Completed and PAT-DX1 + radiation combination (GBM) ü Completed PAT-DX1 +
Slide 16: Upcoming key catalysts and milestones
Upcoming key catalysts and milestones For personal use only CY19 CY20 CY21 3Q 4Q 1Q 2Q 2H CY Single agent + Results from pre- File clinical studies Animal studies to determine appropriate dose and further IND Phase 1 combination evaluate pharmacokinetics and safety clinical trial PAT-DX1 Conjugation
Slide 17: Appendix
For personal use only Appendix
Slide 18: Patrys is a biopharmaceutical company devoted to antibody technologies
Patrys is a biopharmaceutical company devoted to the development of antibody technologies to improve outcomes for cancer patients For personal use only Overview Share price performance (since 1-Jan-2019) Trading information Share price (c) Volume (m) 0.04 80 Share price (23-Jul-19) A$0.024 52 week l
Slide 19: Proven Board and scientific advisory team
Proven Board and scientific advisory team with significant industry, clinical development and commercialisation experience For personal use only John Read | Chairman Dr James Campbell | Chief Executive Officer § 30+ years experience as a Chairman and Director in § 20+ years biotechnology experience
Slide 20: Active intellectual property strategy in place to protect key assets
Active intellectual property strategy in place to protect key assets For personal use only Patrys’ Deoxymab patent portfolio1 Deoxymab patent portfolio 9 Active patent families 5 Granted patents2 19 Patent applications pending1 IP protection granted IP protection pending Patrys’ patent portfolio is
Slide 21: Single agent approach: PAT-DX1 demonstrates significant potential
Single agent approach: 3E10/PAT-DX1 demonstrates significant potential as a single agent For personal use only As a single agent, 3E10/PAT-DX1 has also Results from key single agent studies been shown to… 1600 Control Tumour Volume (mm3) 3E10 1200 Deoxymab 3E10 di- scFV supresses ü Kill various canc
Slide 22: Single agent: pre-clinical mouse study against TNBC brain metastases
Single agent approach: successful pre-clinical mouse model study against TNBC brain metastases1 For personal use only Supressed breast cancer brain metastases Significantly increased survival -93% +86% PAT-DX1 Control PAT-DX1 Control treated treated After 4 weeks of treatment, treated mice showed 93
Slide 23: Combination approach: PAT-DX1 improves survival in glioblastoma model
Combination approach: PAT-DX1 significantly improves survival in an animal model of highly aggressive glioblastoma1 For personal use only Supressed GBM tumour growth Singificantly increased survival 93% 87% 71% 52% 41% 24% Low dose PAT-DX1 PAT-DX1 + low Low dose PAT-DX1 PAT-DX1 + low radiation dose
Slide 24: Combination with standard of care enhances activity
Combination approach: combination of the current standard of care with 3E10/PAT-DX1 enhances activity For personal use only Combination with radiation Combination with chemotherapy Giloma cancer xenograft Glioma cancer cells 700 Control 80 600 Deoxymab 3E10 Tumour Volume (mm3) 500 60 8 Gy % Dead Cel
Slide 25: Conjugation approach: transports drug loaded nanoparticles to the tumour
Conjugation approach: 3E10/DX1 transports drug loaded nanoparticles directly to the tumour, increasing efficacy with lower overall toxicity For personal use only Conjugation approach with PAT-DX1-NP Supress tumour growth PAT-DX1-NPs localise Localises to metastases to metastases supresses tumour gro
Slide 26: Safe Harbour Statement
Safe Harbour Statement For personal use only The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of los
Slide 27: Contact
For personal use only Contact Dr. James Campbell Chief Executive Officer & Managing Director +61 3 9670 3273 info@patrys.com Visit us www.patrys.com Patrys Limited (ASX:PAB)